Candidemia in Cancer Patients: A Prospective, Multicenter Surveillance Study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
In a surveillance study of candidemia in cancer patients that was conducted by the European Organization for Research and Treatment of Cancer, 249 episodes were noted; Candida albicans was isolated in 70% (63) of the 90 cases involving patients with solid tumors (tumor patients) and in 36% (58) of the 159 involving those with hematologic disease (hematology patients). Neutropenia in tumor patients and acute leukemia and antifungal prophylaxis in hematology patients were significantly associated with non-albicans candidemia in a multivariate analysis. Overall 30-day mortality was 39% (97 of 249). In a univariate analysis, Candida glabrata was associated with the highest mortality rate (odds ratio, 2.66). Two multivariate analyses showed that mortality was associated with older age and severity of the underlying disease. Among hematology patients, additional factors associated with mortality were allogeneic bone marrow transplantation, septic shock, and lack of antifungal prophylaxis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies also showed a significant association between receipt of antifungal prophylaxis as well as acute leukemia and a higher incidence of candidemia caused by Candida species other than C. albicans (41).”
In the citing paper
“In cancer patients, Viscoli et al. [18] also suggested that C. glabrata was associated with a higher mortality rate.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [18]
In the citing paper
“Other North American and European investigators confirmed these observations in larger hospital settings [10, 11, 13, 20, 22, 25, 26].”
From Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000 (2004) · cites this paper as [11]
In the citing paper
“Candidemia due to C. parapsilosis has increased in frequency in pediatric populations and appears to be associated with a lower mortality rate than is candidemia due to other species of Candida [110-113].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [113]
In the citing paper
“Candidemia due to C. glabrata may be associated with increased mortality in patients with cancer [113].”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [113]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
(2008) · The Concise Encyclopedia of Statistics · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,670
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174 · cited 1×
“However, this phenomenon has not been confirmed in large prospective studies [26-29].”
ResultSecular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Sague, C. M. B., Jarvis, W. R., & System, N. N. I. S. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 1×
“glabrata) in patients receiving fluconazole [23-25].”
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877 · cited 1×
“glabrata) in patients receiving fluconazole [23-25].”
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance
Hong Nguyen, M., Peacock, J. E., Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R., Wagener, M. M., Rinaldi, M. G., & Yu, V. L. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(95)00010-0 · Cited by 758 · cited 1×
“given about the patients' predisposing conditions [15].”
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679 · cited 2×
“glabrata [3, 4, 1522].”
Background
Cited by
Items 101–200 of 647
Godoy, P., Tiraboschi, I. N., Severo, L. C., Bustamante, B., Calvo, B., de Almeida, L. P., da Matta, D. A., & Colombo, A. L. (2003) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762003000300020 · Cited by 133
“According to data from SENTRY and EORTC surveys, performed between 1997 and 1999, the incidence of C. albicans at European centers ranges from 49% (EORTC) to 59% (SENTRY) of all episodes of candidemia (Viscoli et al. 1999, Pfaller et al. 2001).”
MethodPem�n, J., Cant�n, E., Gobernado, M., & and the Spanish ECMM Working Group on Candidaemia (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1267-5 · Cited by 133
“According to the European Organization for Research and Treatment of Cancer [11], an episode of candidaemia was defined as the isolation of a Candida species from blood culture in a patient with temporally related clinical signs and symptoms.”
MethodResultInfluentialTreatment of invasive candidiasis in the elderly: a review
Dimοpoulos, G., Flevari, A., Θεοδωρακοπούλου, Μ., VELEGRAKI, & Armaganidis (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s39120 · Cited by 132
Hope, W. W., Morton, A., & Eisen, D. P. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2001.1131 · Cited by 130
Hospitalizations for fungal infections after renal transplantation in the United States
Abbott, K. C., Hypolite, I. O., Poropatich, R. K., Hshieh, P., Cruess, D. F., Hawkes, C. A., Agodoa, L. Y. C., & Keller, R. (2001) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2001.30404.x · Cited by 129
Candidemia in French hospitals: incidence rates and characteristics
Richet, H., Roux, P., de Champs, C., Esnault, Y., & Andremont, A. (2002) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2002.00446.x · Cited by 128
Effect of antifungal therapy timing on mortality in cancer patients with candidemia
Taur, Y., Cohen, N., Dubnow, S., Paskovaty, A., & Seo, S. K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00945-09 · Cited by 127
“glabrata infections typically occur in sicker patients (7, 46), individuals for whom incubation times were longer may have experienced higher mortality rates because they were patients with C.”
BackgroundZepelin, M. B.-V., Kunz, L., Rüchel, R., Reichard, U., Weig, M., & Groß, U. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm145 · Cited by 111
“Longitudinal surveillance programmes in the USA and Europe have detected an increase in the prevalence of fungal infections caused by Candida species other than Candida albicans such as Candida glabrata, Candida krusei and Candida parapsilosis.(1,3,4) Moreover, it appears that marked differences exist in species distr…”
BackgroundBlastoschizomyces capitatusInfection in Patients with Leukemia: Report of 26 Cases
Martino, R., Salavert, M., Parody, R., Tomás, J. F., de la Cámara, R., Vázquez, L., Jarque, I., Prieto, E., Sastre, J. L., Gadea, I., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380643 · Cited by 126
“[12] (40%) and Nucci et al.”
BackgroundHebart, H. F., Klingspor, L., Klingebiel, T. E., Loeffler, J., Tollemar, J. G., Ljungman, P. T., Wandt, H., Schaefer‐Eckart, K., Dornbusch, H. J., Meisner, C., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.355 · Cited by 119
Bedini, A., Venturelli, C., Mussini, C., Guaraldi, G., Codeluppi, M., Borghi, V., Rumpianesi, F., Barchiesi, F., & Esposito, R. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01310.x · Cited by 118
“2%, in agreement with previous results [6,23,24].”
BackgroundEpidemiology of invasive fungal infection
Castón, J. J., Rivero, A., & Torre‐Cisneros, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70009-8 · Cited by 117
“[28] Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Lebeau B, et al.”
BackgroundReintroduction of the PLB1 gene into Candida albicans restores virulence in vivo
Mukherjee, P. K., Seshan, K. R., Leidich, S. D., Chandra, J., Cole, G. T., & Ghannoum, M. A. (2001) · Microbiology · doi:10.1099/00221287-147-9-2585 · Cited by 98
“Infections caused by Candida albicans, the most common fungal pathogen of humans (Odds, 1994), have increased significantly in several patient populations, especially immunocompromised individuals (Odom, 1994; Jarvis, 1995; Viscoli et al., 1999).”
BackgroundTortorano, A. M., Biraghi, E., Astolfi, A., Ossi, C., Tejada, M., Farina, C., Perin, S., Bonaccorso, C., Cavanna, C., Raballo, A., et al. (2002) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1261 · Cited by 116
What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead
Bassetti, M., Righi, E., Montravers, P., & Cornely, O. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx445 · Cited by 98
Cryptococcaemia: clinical features and prognostic factors
Jean, S.-S. (2002) · QJM · doi:10.1093/qjmed/95.8.511 · Cited by 109
Treatment options of invasive fungal infections in adults
Marchetti, O., Eggimann, P., Pittet, D., Glauser, M., & Calandra, T. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11392 · Cited by 90
Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome
Atkinson, B. J., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Medical Mycology · doi:10.1080/13693780801968571 · Cited by 98
Gamaletsou, M. N., Walsh, T. J., Zaoutis, T., Pagoni, M., Kotsopoulou, M., Voulgarelis, M., Panayiotidis, P., Vassilakopoulos, T., Angelopoulou, M. K., Marangos, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12312 · Cited by 112
“Invasive candidiasis is associated usually with excess morbidity and mortality, longer hospital stays and higher hospital costs in patients with haematological malignancies [1–5].”
BackgroundIn Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111
“However, there is a great concern because of the increased prevalence of Candida glabrata isolates exhibiting reduced susceptibility to triazole antifungals and of Candida krusei, which has developed an intrinsic resistance to fluconazole and itraconazole due to the empirical use of triazole-based drugs, especially in…”
BackgroundDimopoulos, G., Karabinis, A., Samonis, G., & Falagas, M. E. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0316-2 · Cited by 97
“Risk factors for invasive candidiasis in the ICU have been defined by several studies and include a prolonged hospital stay; the use of broad-spectrum antibiotics, corticosteroids or other immunosuppressants; the administration of total parenteral nutrition, hemodialysis or multiple blood transfusions; prolonged mecha…”
BackgroundInfluentialGuo, L., Yu, S.-Y., Hsueh, P., Al‐Hatmi, A. M. S., Meis, J. F. G. M., Hagen, F., Xiao, M., Wang, H., Barresi, C., Zhou, M., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01505-18 · Cited by 110
“In a study conducted by the Invasive Fungal Infection Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group in cancer patients (5, 23), involving 30 centers and lasting 2 years, 269 cases of fungemia were reported but only 3 were caused by Trichosporon spp.”
The changing epidemiology of invasive fungal infections: new threats
Maschmeyer, G. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.03.006 · Cited by 109
“Reprinted with permission [8].”
Weinberger, M., Leibovici, L., Perez, S., Samra, Z., Ostfeld, I., Levi, I., Bash, E., Turner, D., Goldschmied‐Reouven, A., Regev‐Yochay, G., et al. (2005) · Journal of Hospital Infection · doi:10.1016/j.jhin.2005.02.009 · Cited by 109
Gómez-Gaviria, M., & Mora-Montes, H. M. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s247944 · Cited by 109
Shorr, A. F., Lazarus, D. R., Sherner, J. H., Jackson, W. L., Morrel, M., Fraser, V. J., & Kollef, M. H. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000259379.97694.00 · Cited by 101
Glasmacher, A., Cornely, O., Ullmann, A. J., Wedding, U., Bodenstein, H., Wandt, H., Boewer, C., Pasold, R., Wolf, H.-H., Hänel, M., et al. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki440 · Cited by 105
Ruhnke, M., Behre, G., Buchheidt, D., Christopeit, M., Hamprecht, A. G., Heinz, W., Heußel, C. P., Horger, M., Kurzai, O., Karthaus, M., et al. (2018) · Mycoses · doi:10.1111/myc.12838 · Cited by 106
Incidence of candidaemia and relationship with fluconazole use in an intensive care unit
Bassetti, M., Ansaldi, F., Nicolini, L., Malfatto, E., Molinari, M. P., Mussap, M., Rebesco, B., Bobbio Pallavicini, F., Icardi, G., & Viscoli, C. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp251 · Cited by 92
“Candida glabrata and Candida krusei, has been observed in some studies.(7) – 11 An increasing role for non-albicans species was also noticed in studies performed among intensive care unit (ICU) patients, although the issue is somewhat controversial.”
BackgroundSelf-citationPost, M. J., Lass‐Floerl, C., Gastl, G., & Nachbaur, D. (2007) · Transplant Infectious Disease · doi:10.1111/j.1399-3062.2007.00219.x · Cited by 87
Savini, V., Catavitello, C., Onofrillo, D., Masciarelli, G., Astolfi, D., Balbinot, A., Febbo, F., D’Amario, C., & D’Antonio, D. (2011) · Mycoses · doi:10.1111/j.1439-0507.2010.01960.x · Cited by 84
Chi, H.-W., Yang, Y.-S., Shang, S.-T., Chen, K.-H., Yeh, K.-M., Chang, F.-Y., & Lin, J.-C. (2011) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2010.08.010 · Cited by 103
Roilides, E., Farmaki, E., Evdoridou, J., Francesconi, A., Kasai, M., Filioti, J., Tsivitanidou, M., Sofianou, D., Kremenopoulos, G., & Walsh, T. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.2.735-741.2003 · Cited by 83
“albicans in patients with hematological malignancies, and disseminated infection is associated with high mortality rates (15, 16, 31, 32).”
BackgroundPagano, L., Mele, L., Fianchi, L., Melillo, L. M. A., Martino, B., D’Antonio, D., Tosti, M. E., Posteraro, B., Sanguinetti, M., Trapè, G., et al. (2002) · PubMed · Cited by 101
T-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99
“There are still many mycoses which are hard to treat even with the application of these antifungal agents (1, 5, 21, 24, 25); accordingly, it is imperative that new antifungal agents be developed with broad-spectrum activities, novel mechanisms of action, and fewer side effects.”
BackgroundVardakas, K. Z., Samonis, G., Michalopoulos, A., Soteriades, E. S., & Falagas, M. E. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000208357.05675.c3 · Cited by 91
Candida guilliermondii Fungemia in Patients with Hematologic Malignancies
Girmenia, C., Pizzarelli, G., Cristini, F., Barchiesi, F., Spreghini, E., Scalise, G., & Martino, P. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00356-06 · Cited by 96
Self-citationIn Vitro and In Vivo Antimalarial Activities of T-2307, a Novel Arylamidine
Kimura, A., Nishikawa, H., Nomura, N., Mitsuyama, J., Fukumoto, S., Inoue, N., & Kawazu, S.-I. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05856-11 · Cited by 93
Antifungal chemotherapy: advances and perspectives
Groll, A., & Walsh, T. (2002) · Swiss Medical Weekly · doi:10.4414/smw.2002.09729 · Cited by 76
Krishna, G., Abutarif, M. A., Xuan, F., Martinho, M., Angulo, D. A., & Cornely, O. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.10.1223 · Cited by 94
Arendrup, M. C., Billé, J., Dannaoui, É., Ruhnke, M., Heussel, C. P., & Kibbler, C. C. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.246 · Cited by 94
Sendid, B., Caillot, D., Baccouch-Humbert, B., Klingspor, L., Grandjean, M., Bonnin, A., & Poulain, D. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.10.4551-4558.2003 · Cited by 80
“Candidiasis is the leading cause of invasive fungal infection in patients with malignant hematological disorders (particularly those with acute myeloid leukemia) and bone marrow transplant recipients (29, 35, 44).”
BackgroundSafdar, A., van Rhee, F., Henslee-Downey, J., Singhal, S., & Mehta, J. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703252 · Cited by 93
Velasco, E., Byington, R., Martins, C. A. S., Schirmer, M. R., Dias, L. M. C., & Gonçalves, V. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0077-8 · Cited by 93
The effect of time to antifungal therapy on mortality in candidemia associated septic shock
Patel, G. P., Simon, D., Scheetz, M., Crank, C. W., Lodise, T., & Patel, N. (2009) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181a1afb7 · Cited by 92
“Septic shock developed in 23% (31 of 135) patients with CBSI.”
BackgroundInfluentialRuhnke, M., Cornely, O. A., Schmidt‐Hieber, M., Alakel, N., Boell, B., Buchheidt, D., Christopeit, M., Hasenkamp, J., Heinz, W., Hentrich, M., et al. (2020) · Mycoses · doi:10.1111/myc.13082 · Cited by 88
Yeasts and filamentous fungi in bottled mineral water and tap water from municipal supplies
Yamaguchi, M. U., Rampazzo, . D. C. P., Yamada‐Ogatta, S. F., Nakamura, C. V., Ueda‐Nakamura, T., & Filho, B. P. D. (2007) · Brazilian Archives of Biology and Technology · doi:10.1590/s1516-89132007000100001 · Cited by 86
“glabrata isolates with reduced susceptibilities to triazole antifungals have heightened concerns regarding the empirical use of triazole-based drugs, especially in patients at risk of systemic invasion (Abi-Said et al. 1997; Viscoli et al. 1999; Wingard et al. 1993).”
BackgroundIssues in antifungal susceptibility testing
Johnson, E. M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm427 · Cited by 70
“parapsilosis is associated with a lower mortality rate than other yeast species and may therefore be a weaker pathogen and easier to eradicate.(30,31) It is clear that although breakpoints for susceptibility to the echinocandins have yet to be established, any proposed susceptibility cut-off point should encompass the…”
BackgroundChen, Y.-C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg275 · Cited by 82
The epidemiology of fusariosis in patients with haematological diseases
Girmenia, C., Pagano, L., Corvatta, L., Mele, L., Favero, A. D., & Pr, P. M. F. T. G. I. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02312.x · Cited by 85
Self-citationIncidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours
Haupt, R., Romanengo, M., Fears, T. R., Viscoli, C., & Castagnola, E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00274-x · Cited by 85
“A similar proportion among the Candida isolates has recently been described in a multicentre study [41], but the increase in C.”
BackgroundSelf-citationPauw, B. E. D. (2011) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2011.001 · Cited by 84
França, J. C. B., Ribeiro, C. E., & Queiroz‐Telles, F. (2008) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/s0037-86822008000100005 · Cited by 84
Microbiology of systemic fungal infections.
Chakrabarti, A. (2005) · PubMed · Cited by 82
Puig‐Asensio, M., Ruíz-Camps, I., Fernández‐Ruiz, M., Aguado, J. M., Muñóz, P., Valerio, M., Delgado‐Iribarren, A., Merino, P., Bereciartúa, E., Fortün, J., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2014.12.027 · Cited by 82
“In addition, a shift towards an increasing prevalence of non-albicans species with potentially decreased fluconazole susceptibility has been reported [6,7].”
BackgroundIn search of the holy grail of antifungal therapy.
Chapman, S. W., Sullivan, D. C., & Cleary, J. D. (2008) · PubMed · Cited by 82
Has the Epidemiology of Nosocomial Candidemia Changed?
Puzniak, L., Teutsch, S., Powderly, W., & Polish, L. (2004) · Infection Control & Hospital Epidemiology · doi:10.1086/502452 · Cited by 80
“parapsilosis in 4% to 11% of patients with fungemia.(2,4) By contrast, C.”
BackgroundInvasive fungal infections: evolving challenges for diagnosis and therapeutics
Ellis, M. E. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00022-6 · Cited by 80
Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M., & Graybill, J. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-07 · Cited by 75
“Invasive candidiasis caused by Candida glabrata is of increasing clinical concern due to reports of the increasing frequency of cases and the high mortality rates in patients with multiple comorbidities, including elderly patients, immunocompromised patients with cancer, and patients in intensive care units (4, 15, 24…”
BackgroundNovel strategies to fightCandidaspecies infection
Rodrigues, M. E., Silva, S. M., Azeredo, J., & Henriques, M. (2014) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2014.974500 · Cited by 78
“guilliermondii have been implicated in invasive candidiasis (Ruhnke et al., 2011; Tortorano et al., 2004; Viscoli et al., 1999).”
BackgroundRegulatory mechanisms controlling morphology and pathogenesis in Candida albicans
Kadosh, D. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.005 · Cited by 79
Identification of clinically relevant yeasts by PCR/RFLP
Trost, A., Graf, B., Eucker, J., Sezer, O., Possinger, K., Göbel, U. B., & Adam, T. (2003) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2003.10.007 · Cited by 78
García‐Ruiz, J. C., López-Soria, L., Olazábal, I., Amutio, E., Arrieta-Aguirre, I., Benito, V. V., Pontón, J., & Moragues, M. D. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.02.004 · Cited by 77
Betts, R., Glasmacher, A., Maertens, J., Maschmeyer, G., Vazquez, J. A., Teppler, H., Taylor, A., Lupinacci, R., Sable, C., & Kartsonis, N. (2006) · Cancer · doi:10.1002/cncr.21615 · Cited by 75
The human gut microbiome in health and disease: time for a new chapter?
Lee, J., Bays, D. J., Savage, H. P., & Bäumler, A. J. (2024) · Infection and Immunity · doi:10.1128/iai.00302-24 · Cited by 77
Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit
Bassetti, M., Mikulska, M., & Viscoli, C. (2010) · Critical Care · doi:10.1186/cc9239 · Cited by 57
“Indeed, previous use of fl uconazole has been found to be a risk factor for the presence of non-albicans fungaemia [24,25,35] even though some studies did not fi nd this association [23].”
ResultSelf-citationMicrosatellite Marker Analysis as a Typing System for Candida glabrata
Foulet, F., Nicolas, N., Eloy, O., Botterel, F., Gantier, J.-C., Costa, J.-M., & Bretagne, S. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4574-4579.2005 · Cited by 68
“albicans (14, 22) and the high mortality rate of bloodstream infections (28, 29).”
BackgroundKamran, M., Calcagno, A.-M., Findon, H., Bignell, E., Jones, M. D., Warn, P., Hopkins, P., Denning, D. W., Butler, G., Rogers, T., et al. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.2.546-552.2004 · Cited by 75
“overall mortality rate than other Candida species (11, 26).”
BackgroundEchinocandins: A ray of hope in antifungal drug therapy
Grover, N. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.62396 · Cited by 75
“[3] They also show a reduced susceptibility to azole antifungals.”
Hirano, R., Sakamoto, Y., Kudo, K., & Ohnishi, M. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s80677 · Cited by 74
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
Bow, E. J., Evans, G., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R., Shafran, S. D., Sheppard, D., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 70
Del Bono, V., Delfino, E., Furfaro, E., Mikulska, M., Nicco, E., Bruzzi, P., Mularoni, A., Bassetti, M., & Viscoli, C. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05408-11 · Cited by 58
“Candida has been reported to be one of the most frequent cause of associated bloodstream infections in different health care settings (16, 26, 28) and carries an attributable mortality ranging from 5 to 71% (8).”
BackgroundSelf-citationAquino, V. R., Lunardi, L. W., Goldani, L. Z., & Barth, A. L. (2005) · Brazilian Journal of Infectious Diseases · doi:10.1590/s1413-86702005000500009 · Cited by 58
Fungal infections in nontransplant patients with hematologic malignancies
Segal, B. H., Bow, E. J., & Menichetti, F. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00043-0 · Cited by 73
“mortality was 39%, with increased mortality occurring in older patients, in those with poorly controlled malignancy, and in cases in which Candida (Torulopsis) glabrata was isolated [35].”
BackgroundTreatment of invasive Candida and invasive Aspergillus infections in adult haematological patients
Herbrecht, R., Flückiger, U. M., Gachot, B., Ribaud, P., Thiébaut, A., & Cordonnier, C. (2007) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2007.06.007 · Cited by 73
Primary antifungal prophylaxis in leukaemia patients
Maertens, J. A., Frère, P., Lass‐Flörl, C., Heinz, W., & Cornely, O. A. (2007) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2007.06.006 · Cited by 72
Occurrence, presentation and treatment of candidemia
Mikulska, M., Del Bono, V., Ratto, S., & Viscoli, C. (2012) · Expert Review of Clinical Immunology · doi:10.1586/eci.12.52 · Cited by 71
Self-citationAntifungal Resistance Among Candida Species
Klepser, M. E. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.124s.34511 · Cited by 71
Changing spectrum of invasive candidiasis and its therapeutic implications
Singh, N. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00004.x · Cited by 71
Rapid identification of Candida species in oral rinse solutions by PCR
Liguori, G., Lucariello, A., Colella, G., Luca, A. D., & Marinelli, P. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2006.040782 · Cited by 70
“etc) has also been observed and associated with long-term treatment with amphotericin and fluconazole.”
BackgroundMichallet, M., & Ito, J. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1178 · Cited by 69
“ceptibility (eg, azole- and echinocandin-resistant C glabrata, C parapsilosis, and C albicans).(11,12,13) At a”
BackgroundInvasive fungal infections in transplant recipients
Vázquez, J. A., Miceli, M. H., & Alangaden, G. J. (2013) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936113491936 · Cited by 69
“…chemotherapy-induced neutropenia: fluconazole 400 mg daily, posaconazole 200 mg three times per day, or caspofungin 50 mg daily is recommended during induction chemotherapy for the duration of neutropenia [Viscoli et al. 1999; Husain et al. 2006; Ullmann and Cornely, 2006; van Burik et al. 2004].”
BackgroundSafdar, A., Perlin, D. S., & Armstrong, D. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00423-6 · Cited by 69
Recommendations for the treatment of established fungal infections
Thursky, K., Playford, E. G., Seymour, J. F., Sorrell, T. C., Ellis, D. H., Guy, S., Gilroy, N. M., Chu, J., & Shaw, D. (2008) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01725.x · Cited by 68
Liu, C. Y., Huang, L. J., Wang, W. S., Chen, T. L., Yen, C. C., Yang, M. H., Hsiao, L. T., Liu, C. Y., Chen, P. M., & Chiou, T. J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2008.12.008 · Cited by 67
Mixed Fungemia: Incidence, Risk Factors, and Mortality in a General Hospital
Jensen, J., Munoz, P., Guinea, J., Rodríguez‐Créixems, M., Peláez, T., & Bouza, E. (2007) · Clinical Infectious Diseases · doi:10.1086/518175 · Cited by 65
Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999
Cuenca-Estrella, M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf060 · Cited by 53
Lortholary, O., Aşçıoğlu, S., Moreau, P., Herbrecht, R., Marinus, A., Casassus, P., de Pauw, B., & Denning, D. W. (2000) · Clinical Infectious Diseases · doi:10.1086/313592 · Cited by 65
“The latter observation is cons stent with other dat generated by t e EORTC/IFICG in a prospective survey on fungemia in patients with [16].”
MethodSelf-citationWise, M. G. G., Healy, M., Reece, K., Smith, R. J., Walton, D., Dutch, W., Renwick, A., Huong, J., Young, S., Tarrand, J. J., et al. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47106-0 · Cited by 65
“…PCR. 778 47106 G 2007 SGM Printed in Great Britain Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11 On: Wed, 12 Dec 2018 18:45:27 Vermitsky & Edlind, 2004) and are associated with high failure rates of azole-based treatment (Tortorano et al., 2004; Viscoli et al., 1999).”
BackgroundInfluentialINFECTIOUS COMPLICATIONS OF FEBRILE LEUKOPENIA
Giamarellou, H., & Antoniadou, A. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70156-2 · Cited by 64
Dupont, B. F., Lortholary, O., Ostrosky-Zeichner, L., Stucker, F., & Yeldandi, V. (2009) · Critical Care · doi:10.1186/cc8117 · Cited by 58
“The all-cause mortality rate at day 30 in our analysis was in general agreement with data derived from observational studies [4,38-51].”
ResultEpithelial hypoxia maintains colonization resistance against Candida albicans
Savage, H. P., Bays, D. J., Tiffany, C. R., Gonzalez, M. A. F., Bejarano, E. J., de Carvalho, T. P., Luo, Z. L., Masson, H. L. P., Nguyen, H., Santos, R. L., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.05.008 · Cited by 63
Presterl, E., Daxböck, F., Graninger, W. B., & Willinger, B. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01812.x · Cited by 63
“While studies in the USA have revealed an association between candidaemia and the number of hospital beds and ⁄ or an academic affiliation [3], European studies have shown a widely varying incidence of invasive fungal infections in special centres, patient groups and countries [4–8].”
ResultLagrou, K., Verhaegen, J., Peetermans, W. E., Rijdt, T. D., Maertens, J. A., & Wijngaerden, E. V. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0339-8 · Cited by 63
“krusei) in this patient group in the ECMM survey and in the surveillance study performed by the European Organization for Research and Treatment of Cancer (EORTC) [15].”
MethodFungal infections in patients undergoing blood and marrow transplantation
Marr, K. A., & Bowden, R. A. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.010403.x · Cited by 63
Mariette, C., Tavernier, E., Hocquet, D., Huynh, A., Isnard, F., Legrand, F., Lhéritier, V., Raffoux, E., Dombret, H., Ifrah, N., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1204652 · Cited by 62
Invasive candidiasis in pediatric intensive care units
Singhi, S. C., & Deep, A. (2009) · The Indian Journal of Pediatrics · doi:10.1007/s12098-009-0219-6 · Cited by 62
Kontoyiannis, D. P., Reddy, B. T., Hanna, H., Bodey, G. P., Tarrand, J., & Raad, I. I. (2002) · Infection Control & Hospital Epidemiology · doi:10.1086/502104 · Cited by 55
Rodríguez-Pardo, D., the Barcelona Candidemia Project Study Group, Almirante, B., Cuenca‐Estrella, M., Rodríguez-Tudela, J. L., Mensa, J., Ayats, J., Sánchez, F., & Pahissa, A. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03208.x · Cited by 60
“glabrata were more prevalent [7,14,28].”
BackgroundPham, A. N., Bubalo, J. S., & Lewis, J. S. (2016) · Mycoses · doi:10.1111/myc.12452 · Cited by 60
Metadata
- Authors
- Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., De Pauw, B., Meunier, F., & the Invasive Fungal Infection Group of the EORTC
- Affiliations
- University of Genoa (IT)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1999-05
- Volume
- 28
- Issue
- 5
- Pages
- 1071-1079
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2126536749
- Cited by
- 601
- References
- 29
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 11 · 2022: 6 · 2021: 9 · 2020: 9 · 2019: 8 · 2018: 16 · 2017: 15 · 2016: 16 · 2015: 22 · 2014: 27 · 2013: 31 · 2012: 25
- FWCI
- 21.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, invasive fungal infections, cancer patients, Candida albicans, non-albicans Candida, Candida glabrata, solid tumors, hematologic malignancies, acute leukemia, neutropenia, antifungal prophylaxis, allogeneic bone marrow transplantation, septic shock, 30-day mortality, risk factors
- MeSH terms
- Adult, Aged, Aged, 80 and over, Candida albicans, Candidiasis, Child, Child, Preschool, Cross Infection, Female, Humans, Male, Middle Aged, Neoplasms, Neutropenia, Population Surveillance, Prospective Studies, Multivariate Analysis, Survival Analysis, Hematologic Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.